Atypical skin lesions
Michael Findlay
Department of Surgery, Stanford University, Stanford, CA, USA
Division of Cancer Surgery, The Peter MacCallum Cancer Center, East Melbourne, Australia
The University of Melbourne Department of Surgery, Melbourne, Australia
Search for more papers by this authorMichael A. Henderson
Division of Cancer Surgery, The Peter MacCallum Cancer Center, East Melbourne, Australia
Search for more papers by this authorMichael Findlay
Department of Surgery, Stanford University, Stanford, CA, USA
Division of Cancer Surgery, The Peter MacCallum Cancer Center, East Melbourne, Australia
The University of Melbourne Department of Surgery, Melbourne, Australia
Search for more papers by this authorMichael A. Henderson
Division of Cancer Surgery, The Peter MacCallum Cancer Center, East Melbourne, Australia
Search for more papers by this authorRoss D. Farhadieh BSc(Med)Hons, MBBS, MD, EBOPRASF, FRACS(Plast), FRCS(Plast)
Panthea Plastic Surgery Clinics, Sydney and Canberra, Australia and Australian National University, Canberra, Australia
Search for more papers by this authorNeil W. Bulstrode BSc(Med)Hons, MBBS, MD, FRCS(Plast)
Clinical Lead Plastic Surgery
Great Ormond Street Hospital, London, UK
Search for more papers by this authorSabrina Cugno MD, MSc, FRCSC
Assistant Professor
McGill University, Department of Plastic Surgery, Montreal Children's Hospital, Montreal, Canada
Search for more papers by this authorSummary
The atypical skin lesions are a diverse group of tumours that are uncommon but clinically important. They include a spectrum from benign lesions through to those that demonstrate local invasion and/or distant metastatic potential. Since these lesions are only seen infrequently during clinical practice, it is important to have a solid grounding in the general principles of their management. We also cover some common surgically relevant lesions of the skin, including common types of cysts. A clear understanding of cysts and their aetiology is important to direct their management. We have divided the atypical lesions into benign or malignant and then by their cell/tissue of origin to provide a framework for their study. Such a framework is not perfect due to our evolving understanding of the molecular and cellular bases of these tumours, but it provides a foundation for their study.
References
- National Cancer Institute at the National Institutes of Health. HPV and cancer. http://cancer.gov/cancertopics/factsheet/Risk/HPV (accessed 19 December 2013).
- Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Seminars in Oncology 2004; 31(6): 744–754.
- Layegh P, Sharifi-Sistani N, Abadian M, Moghiman T. Brooke-Spiegler syndrome. Indian Journal of Dermatology, Venereology, and Leprology 2008; 74(6): 632–634.
- Wu YH. Folliculosebaceous cystic hamartoma or trichofolliculoma? A spectrum of hamartomatous changes inducted by perifollicular stroma in the follicular epithelium. Journal of Cutaneous Pathology 2008; 35(9): 843–848.
- Stern JB, Stout DA. Trichofolliculoma showing perineural invasion. Trichofolliculocarcinoma? Archives of Dermatology 1979; 115(8): 1003–1004.
- Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics 1997; 16(1): 64–67.
- Hogan DJ. Sebaceous hyperplasia. Emedicine 2012. http://emedicine.medscape.com/article/1059368 (accessed 19 December 2013).
- Salim A, Reece SM, Smith AG, et al. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. Journal of the American Academy of Dermatology 2006; 55(5): 878–881.
- Yu C, Shahsavari M, Stevens G, Liskanich R, Horowitz D. Isotretinoin as monotherapy for sebaceous hyperplasia. Journal of Drugs in Dermatology 2010; 9(6): 699–701.
- Friedman SJ, Butler DF. Syringoma presenting as milia. Journal of the American Academy of Dermatology 1987; 16(2 Part 1): 310–314.
- Bowen S, Gill M, Lee DA, et al. Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation. Journal of Investigative Dermatology 2005; 124(5): 919–920.
- Naversen DN, Trask DM, Watson FH, Burket JM. Painful tumors of the skin: “LEND AN EGG”. Journal of the American Academy of Dermatology 1993; 28(2 Part 2): 298–300.
- Yamamoto T. Dermatofibroma: a possible model of local fibrosis with epithelial/mesenchymal cell interaction. Journal of the European Academy of Dermatology and Venereology 2009; 23(4): 371–375.
- Sellheyer K, Smoller BR. Dermatofibroma: upregulation of syndecan-1 expression in mesenchymal tissue. American Journal of Dermatopathology 2003; 25(5): 392–398.
- Skroza N, Rotolo S, Ceccarelli S, et al. Modulation of the expression of the FGFR2-IIIb and FGFR2-IIIc molecules in dermatofibroma. Journal of Dermatological Science, 2008; 51(1): 53–57.
- Pierson, J. Dermatofibroma. eMedicine 2012. http://emedicine.medscape.com/article/1056742-clinical (accessed 21 December 2013).
- Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas: a prospective morphological study of 412 cases. Archives of Dermatology 2008; 144(1): 75–83.
- Behan FC, Rozen WM, Kwee MM, Kapila S, Fairbank S, Findlay MW. Oncologic clearance with preservation of reconstructive options: literature review and the ‘delayed reconstruction after pathology evaluation (DRAPE)’ technique. ANZ Journal of Surgery 2012; 82(11): 780–785.
- Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. Journal of the American Academy of Dermatology 2008; 58(3): 375–381.
- Miller SJ, Alam M, Andersen J, et al. Merkel cell carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN 2009; 7(3): 322–332.
- Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual ( 7th edn), p. 649. New York: Springer; 2010.
- Tai PT, Yu E, Tonita J, Gilchrist J. Merkel cell carcinoma of the skin. Journal of Cutaneous Medicine and Surgery 2000; 4(4): 186–195.
- Victor NS, Morton B, Smith JW. Merkel cell cancer: is prophylactic lymph node dissection indicated? American Journal of Surgery 1996; 62(11): 879–882.
- Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Annals of Surgical Oncology 1997; 4(5): 389–395.
- Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study – TROG 96:07. Journal of Clinical Oncology 2003; 21(23): 4371–4376.
- Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. Journal of Surgical Oncology 2013; 108(1): 57–62.
- Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Modern Pathology 2006; 19(Suppl 2): S93–S126.
- Yu JB, Blitzblau RC, Patel SC, Decker RH, Wilson LD. Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin. American Journal of Clinical Oncology, 2010; 33(2): 125–127.
- Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. American Journal of Surgery and Pathology 2001; 25(6): 710–720.
- Hegarty PK,Suh J, Fisher MB, et al. Penoscrotal extramammary Paget's disease: the University of Texas M. D. Anderson Cancer Center contemporary experience. Journal of Urology 2011; 186(1): 97–102.
- Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008; 113(3): 616–627.
- Henderson MT, Hollmig ST. Malignant fibrous histiocytoma: changing perceptions and management challenges. Journal of the American Academy of Dermatology 2012; 67(6): 1335–1341.
- Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. Journal of Clinical Oncology 2005; 23(30): 7669–7675.
- Voth H, Landsberg J, Hinz T, et al. Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. Journal of European Academy of Dermatology and Venereology 2011; 25(12): 1385–1391.
- Miller SJ, Alam M, Andersen JS, et al. Dermatofibrosarcoma protuberans. Journal of the National Comprehensive Cancer Network: JNCCN 2012; 10(3): 312–318.
- Ha SY, Lee SE, Kwon MJ, et al. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications. Human Pathology 2013; 44(7): 1300–1309.
- Lindner NJ, Scarborough MT, Powell GJ, Spanier S, Enneking WF. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. European Journal of Surgical Oncology 1999; 25(4): 392–397.
- Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. American Journal of Dermatopathology 2010; 32(6): 533–540.
- Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma”. American Journal of Surgical Pathology 2011; 35(4): 599–607.
- Perez MC, Padhya TA, Messina JL, et al. Cutaneous angiosarcoma: a single-institution experience. Annals of Surgical Oncology 2013; 20(11): 3391–3397.